These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38413275)

  • 41. Effectiveness and Adverse Events of Use of Natalizumab in a Brazilian Cohort of Patients With Multiple Sclerosis.
    Deslandes MQ; Alves PT; Alvarenga MP; Lessa VCC; Camargo S; Alvarenga RMP; Vasconcelos CC
    Clin Ther; 2020 Jul; 42(7):1292-1301. PubMed ID: 32593474
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients.
    Esposito F; Ferrè L; Clarelli F; Rocca MA; Sferruzza G; Storelli L; Radaelli M; Sangalli F; Moiola L; Colombo B; Martinelli Boneschi F; Comi G; Filippi M; Martinelli V
    J Neurol; 2018 Apr; 265(4):896-905. PubMed ID: 29435643
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy.
    Hellwig K; Tokic M; Thiel S; Esters N; Spicher C; Timmesfeld N; Ciplea AI; Gold R; Langer-Gould A
    JAMA Netw Open; 2022 Jan; 5(1):e2144750. PubMed ID: 35072719
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lessons learned after 20 years of real-world experience with natalizumab.
    Khatri BO; Olapo T; Beals S; Lindman E; Perea T; Van Zealand P; Metzger RR
    Mult Scler Relat Disord; 2023 Dec; 80():105048. PubMed ID: 37866023
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study.
    O'Connor P; Goodman A; Kappos L; Lublin F; Polman C; Rudick RA; Hauswirth K; Cristiano LM; Forrestal F; Duda P
    Neurology; 2014 Jul; 83(1):78-86. PubMed ID: 24898925
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
    Khalid F; Tauhid S; Chua AS; Healy BC; Stankiewicz JM; Weiner HL; Bakshi R
    Int J Neurosci; 2017 May; 127(5):396-403. PubMed ID: 27143245
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
    Algahtani H; Shirah B; Abobaker H; Alghanaim N; Kamel F
    Clin Neuropharmacol; 2018; 41(6):199-201. PubMed ID: 30234558
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis.
    Prosperini L; Saccà F; Cordioli C; Cortese A; Buttari F; Pontecorvo S; Bianco A; Ruggieri S; Haggiag S; Brescia Morra V; Capra R; Centonze D; Di Battista G; Ferraro E; Francia A; Galgani S; Gasperini C; Millefiorini E; Mirabella M; Pozzilli C
    J Neurol; 2017 Feb; 264(2):284-294. PubMed ID: 27878443
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increased relapse activity for multiple sclerosis natalizumab users who become nonpersistent: a retrospective study.
    McQueen RB; Livingston T; Vollmer T; Corboy J; Buckley B; Allen RR; Nair K; Campbell JD
    J Manag Care Spec Pharm; 2015 Mar; 21(3):210-8b. PubMed ID: 25726030
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab.
    Dekker I; Leurs CE; Hagens MHJ; van Kempen ZLE; Kleerekooper I; Lissenberg-Witte BI; Barkhof F; Uitdehaag BMJ; Balk LJ; Wattjes MP; Killestein J
    Mult Scler Relat Disord; 2019 Aug; 33():82-87. PubMed ID: 31174043
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia.
    Alharbi MA; Aldosari F; Althobaiti AH; Abdullah FM; Aljarallah S; Alkhawajah NM; Alanazi M; AlRuthia Y
    BMC Health Serv Res; 2023 May; 23(1):552. PubMed ID: 37237257
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
    Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
    Mult Scler; 2018 May; 24(6):777-785. PubMed ID: 29685071
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis.
    Ryerson LZ; Foley JF; Defer G; Cohen JA; Arnold DL; Butzkueven H; Cutter G; Giovannoni G; Killestein J; Wiendl H; Sinks S; Kuhelj R; Bodhinathan K; Lasky T
    Mult Scler Relat Disord; 2023 Apr; 72():104561. PubMed ID: 36931078
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

  • 55. COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients.
    Bisecco A; Matrone F; Capobianco M; De Luca G; Filippi M; Granella F; Lus G; Marfia GA; Mirabella M; Patti F; Trojano M; Mascolo A; Copetti M; Tedeschi G; Gallo A;
    J Neurol; 2024 Feb; 271(2):699-710. PubMed ID: 37982852
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Delay from treatment start to full effect of immunotherapies for multiple sclerosis.
    Roos I; Leray E; Frascoli F; Casey R; Brown JWL; Horakova D; Havrdova EK; Trojano M; Patti F; Izquierdo G; Eichau S; Onofrj M; Lugaresi A; Prat A; Girard M; Grammond P; Sola P; Ferraro D; Ozakbas S; Bergamaschi R; Sá MJ; Cartechini E; Boz C; Granella F; Hupperts R; Terzi M; Lechner-Scott J; Spitaleri D; Van Pesch V; Soysal A; Olascoaga J; Prevost J; Aguera-Morales E; Slee M; Csepany T; Turkoglu R; Sidhom Y; Gouider R; Van Wijmeersch B; McCombe P; Macdonell R; Coles A; Malpas CB; Butzkueven H; Vukusic S; Kalincik T; ;
    Brain; 2020 Sep; 143(9):2742-2756. PubMed ID: 32947619
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts.
    Sharmin S; Lefort M; Andersen JB; Leray E; Horakova D; Havrdova EK; Alroughani R; Izquierdo G; Ozakbas S; Patti F; Onofrj M; Lugaresi A; Terzi M; Grammond P; Grand'Maison F; Yamout B; Prat A; Girard M; Duquette P; Boz C; Trojano M; McCombe P; Slee M; Lechner-Scott J; Turkoglu R; Sola P; Ferraro D; Granella F; Prevost J; Maimone D; Skibina O; Buzzard K; Van der Walt A; Van Wijmeersch B; Csepany T; Spitaleri D; Vucic S; Casey R; Debouverie M; Edan G; Ciron J; Ruet A; De Sèze J; Maillart E; Zephir H; Labauge P; Defer G; Lebrun-Frénay C; Moreau T; Berger E; Clavelou P; Pelletier J; Stankoff B; Gout O; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Casez O; Cabre P; Montcuquet A; Wahab A; Camdessanché JP; Maurousset A; Patry I; Hankiewicz K; Pottier C; Maubeuge N; Labeyrie C; Nifle C; Laplaud D; Koch-Henriksen N; Sellebjerg FT; Soerensen PS; Pfleger CC; Rasmussen PV; Jensen MB; Frederiksen JL; Bramow S; Mathiesen HK; Schreiber KI; Magyari M; Vukusic S; Butzkueven H; Kalincik T;
    CNS Drugs; 2021 Nov; 35(11):1217-1232. PubMed ID: 34536228
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
    Koch-Henriksen N; Magyari M; Sellebjerg F; Soelberg Sørensen P
    Mult Scler; 2017 Feb; 23(2):234-241. PubMed ID: 27055806
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
    Zivadinov R; Hojnacki D; Bergsland N; Kennedy C; Hagemeier J; Melia R; Ramasamy DP; Durfee J; Carl E; Dwyer MG; Weinstock-Guttman B
    Eur J Neurol; 2016 Jun; 23(6):1101-9. PubMed ID: 26998905
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis.
    Boz C; Ozakbas S; Terzi M; Karabudak R; Sevim S; Turkoglu R; Soysal A; Balcı BP; Efendi H; Turan ÖF; Yüceyar N; Yetkin MF; Karahan SZ; Demirkıran M; Guler S; Agan K; Kıylıoğlu N; Baba C; Tuncer A; Köseoğlu M
    Neurol Sci; 2023 Jun; 44(6):2121-2129. PubMed ID: 36689010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.